Intermediatemolecular

Chromosomal Mutations

Overview

Chromosomal mutations rearrange large DNA segments: deletions and duplications change copy number; inversions and translocations reorder without changing amount; aneuploidy changes whole-chromosome counts. Consequences range from mild (some duplications) to severe (cri-du-chat deletion, Philadelphia chromosome translocation in CML, Down syndrome trisomy 21).

Learning objectives

  • Define deletion, duplication, inversion, translocation
  • Explain aneuploidy and nondisjunction
  • Give clinical examples of each type
  • Describe how translocations cause cancer

Deletions and duplications

Deletions remove segments: cri-du-chat (5p deletion) causes cat-like cry and intellectual disability. Duplications add copies: Charcot-Marie-Tooth 1A is usually a PMP22 duplication; MECP2 duplication causes severe neurodevelopmental disorder. Copy-number variants (CNVs) collectively cover ~10% of the genome.

Dosage matters

Many genes are dosage-sensitive: too much or too little protein disrupts development.

Inversions and translocations

Inversions flip a segment (paracentric: not including centromere; pericentric: including it); carriers are usually healthy but produce unbalanced gametes. Reciprocal translocations swap segments between chromosomes; Robertsonian translocations fuse acrocentrics (a cause of familial Down syndrome).

Healthy carriers, risky gametes

Balanced rearrangement carriers are phenotypically normal but face infertility, miscarriage, and unbalanced offspring.

The Philadelphia chromosome

t(9;22) fuses BCR and ABL1, creating a constitutively active tyrosine kinase driving chronic myeloid leukemia. Imatinib (Gleevec), designed against BCR-ABL, turned CML from fatal to manageable: the first triumph of targeted cancer therapy, born from understanding a translocation.

Translocation -> targeted drug

BCR-ABL is the paradigm: a chromosomal rearrangement creating a druggable oncogene.

Aneuploidy and nondisjunction

Nondisjunction (homologs or chromatids failing to separate) produces trisomy/monosomy gametes. Autosomal trisomies are mostly lethal; trisomy 21 survives (Down syndrome). Sex chromosome aneuploidies (XO Turner, XXY Klinefelter) are milder because X-inactivation and Y gene paucity buffer dosage.

Maternal age effect

Trisomy 21 risk rises from ~1/1500 at 20 to ~1/100 at 40: aging oocytes missegregate more.

Key points

  • Deletions/duplications alter copy number (dosage effects)
  • Inversions/translocations reorder; balanced carriers are healthy but reproductively at risk
  • t(9;22) BCR-ABL causes CML; imatinib targets it
  • Nondisjunction causes aneuploidy; trisomy 21 risk rises with maternal age

Common misconceptions

✗ Myth: Balanced translocation carriers are always ill.

✓ Truth: They are usually healthy; the risk is unbalanced gametes causing infertility, miscarriage, or affected children.

✗ Myth: All trisomies are equally severe.

✓ Truth: Most autosomal trisomies are embryonic lethal; 21, 18, and 13 survive to birth with decreasing viability; sex chromosome aneuploidies are mildest.

Practice questions

Q1. The Philadelphia chromosome is
  1. A deletion
  2. t(9;22) creating BCR-ABL
  3. Trisomy 21
  4. An inversion
Answer: B.

The reciprocal translocation fuses BCR and ABL1 into an oncogenic kinase.

Q2. Cri-du-chat syndrome is caused by
  1. Trisomy 21
  2. 5p deletion
  3. XYY
  4. Fragile X
Answer: B.

Deletion of the short arm of chromosome 5.

Q3. Nondisjunction during meiosis I produces gametes that are
  1. Normal
  2. n+1 and n-1
  3. Diploid
  4. Without DNA
Answer: B.

Homologs failing to separate give one extra and one missing chromosome.

Click a question to reveal the answer and explanation.

Frequently asked questions

What is chromothripsis?

Catastrophic shattering and random reassembly of one chromosome in a single event, found in some cancers and congenital disorders.

Why are Robertsonian translocations special?

They fuse two acrocentric chromosomes at centromeres; carriers have 45 chromosomes but normal phenotype, with Down syndrome risk for 14;21 carriers.

How does imatinib work?

It occupies BCR-ABL's ATP-binding pocket, blocking the constitutive kinase signaling driving CML.